485 related articles for article (PubMed ID: 8850360)
21. Gadolinium Retention in Erythrocytes and Leukocytes From Human and Murine Blood Upon Treatment With Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging.
Di Gregorio E; Furlan C; Atlante S; Stefania R; Gianolio E; Aime S
Invest Radiol; 2020 Jan; 55(1):30-37. PubMed ID: 31503081
[TBL] [Abstract][Full Text] [Related]
22. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
[TBL] [Abstract][Full Text] [Related]
23. Signal Enhancement and Enhancement Kinetics of Gadobutrol, Gadoteridol, and Gadoterate Meglumine in Various Body Regions: A Comparative Animal Study.
Knobloch G; Frenzel T; Pietsch H; Jost G
Invest Radiol; 2020 Jun; 55(6):367-373. PubMed ID: 31985602
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Gd-EOB-DTPA and Gd-DTPA for contrast-enhanced MR imaging of liver tumors.
Clemént O; Mühler A; Vexler VS; Kuwatsuru R; Berthezène Y; Rosenau W; Brasch RC
J Magn Reson Imaging; 1993; 3(1):71-7. PubMed ID: 8428104
[TBL] [Abstract][Full Text] [Related]
25. Gadolinium Presence in the Brain After Administration of the Liver-Specific Gadolinium-Based Contrast Agent Gadoxetate: A Systematic Comparison to Multipurpose Agents in Rats.
Jost G; Frenzel T; Boyken J; Schoeckel L; Pietsch H
Invest Radiol; 2019 Aug; 54(8):468-474. PubMed ID: 30932931
[TBL] [Abstract][Full Text] [Related]
26. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.
Grazioli L; Morana G; Caudana R; Benetti A; Portolani N; Talamini G; Colombari R; Pirovano G; Kirchin MA; Spinazzi A
Invest Radiol; 2000 Jan; 35(1):25-34. PubMed ID: 10639033
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a Gadolinium-Based Nanoparticle (AGuIX) for Contrast-Enhanced MRI of the Liver in a Rat Model of Hepatic Colorectal Cancer Metastases at 9.4 Tesla.
Fries P; Morr D; Müller A; Lux F; Tillement O; Massmann A; Seidel R; Schäfer T; Menger MD; Schneider G; Bücker A
Rofo; 2015 Dec; 187(12):1108-15. PubMed ID: 26361379
[TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1994 Dec; 29(12):1050-6. PubMed ID: 7721546
[TBL] [Abstract][Full Text] [Related]
29. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
30. Experimental trials with Gd(DO3A)--a nonionic magnetic resonance contrast agent.
Runge VM; Kaufman DM; Wood ML; Adelman LS; Jacobson S
Int J Rad Appl Instrum B; 1989; 16(6):561-7. PubMed ID: 2606711
[TBL] [Abstract][Full Text] [Related]
31. An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography.
Yang CT; Chandrasekharan P; He T; Poh Z; Raju A; Chuang KH; Robins EG
Biomaterials; 2014 Jan; 35(1):327-36. PubMed ID: 24138829
[TBL] [Abstract][Full Text] [Related]
32. Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation.
Idée JM; Berthommier C; Goulas V; Corot C; Santus R; Hermine C; Schaefer M; Bonnemain B
Biometals; 1998 Apr; 11(2):113-23. PubMed ID: 9542065
[TBL] [Abstract][Full Text] [Related]
33. High-dose applications of gadolinium chelates in magnetic resonance imaging.
Runge VM; Kirsch JE; Thomas GS
Magn Reson Med; 1991 Dec; 22(2):358-63. PubMed ID: 1812371
[TBL] [Abstract][Full Text] [Related]
34. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media.
Puttagunta NR; Gibby WA; Puttagunta VL
Invest Radiol; 1996 Oct; 31(10):619-24. PubMed ID: 8889650
[TBL] [Abstract][Full Text] [Related]
35. Delayed magnetic resonance hepatic imaging with gadolinium-DTPA.
Nelson RC; Umpierrez ME; Chezmar JL; Bernardino ME
Invest Radiol; 1988 Jul; 23(7):509-11. PubMed ID: 3170138
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength.
Fries P; Massmann A; Robert P; Corot C; Laschke MW; Schneider G; Buecker A; Müller A
Invest Radiol; 2019 Sep; 54(9):549-558. PubMed ID: 31033675
[TBL] [Abstract][Full Text] [Related]
37. Dynamic contrast-enhanced magnetic resonance imaging in a model of splenic metastasis.
Runge VM; Williams NM
Invest Radiol; 1998 Jan; 33(1):45-50. PubMed ID: 9438509
[TBL] [Abstract][Full Text] [Related]
38. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
39. Neurotoxicity of gadolinium contrast agents for magnetic resonance imaging in rats with osmotically disrupted blood-brain barrier.
Takahashi M; Tsutsui H; Murayama C; Miyazawa T; Fritz-Zieroth B
Magn Reson Imaging; 1996; 14(6):619-23. PubMed ID: 8897365
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
